ClinicalTrials.gg
Not yet recruitingNCT06828419Updated Apr 3, 2025

A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery

An interventional study of Domestic single-port laparoscopic surgery system in Adenopathy, Uterine Fibroids and Ovarian Cysts, sponsored by Second Affiliated Hospital of Wenzhou Medical University. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Second Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

In this study, a prospective study is used to select patients who will undergo intra-abdominal endoscopic single-port surgery system for benign gynecological diseases from February 2025 to December 2026 in the Second Affiliated Hospital of Wenzhou Medical University, including hysterectomy, myomectomy, ovarian cyst removal and adnexectomy. The study will perform statistical analysis to evaluate the feasibility and the main factors affecting the safety of intra-abdominal endoscopic single-port surgery system(SR-ENS-600) used in gynecological day surgery.

02

Conditions studied

  • Adenopathy
  • Uterine Fibroids
  • Ovarian Cysts
  • Adnexal Mass
  • Ovarian Diseases
  • Adnexal Cyst
  • Adnexal Diseases

Keywords

  • robotic-assisted laparoscopic single-site surgery (R-LESS)
  • single-port robot system (SPRS)
  • day surgery
03

In context

Lymphadenopathy

77 studies on the registry are indexed under Lymphadenopathy; 14 are open to participants now.

This study's planned enrollment of 63 is below the median of 101 across 52 interventional studies indexed under Lymphadenopathy.

Browse Lymphadenopathy studies →

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 137 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 to 75 years old, with a (BMI) of no more than 32 kg/m2;
  2. Conscious, no history of mental illness, accompanied by an adult during the perioperative period;
  3. Educate the subjects, who are willing to undergo day surgery, understand and accept the surgical method and anesthesia method;
  4. Subjects and families understand perioperative care and are willing and able to complete post-discharge care;
  5. Elective surgery, no serious complications affecting the operation and prognosis, aCCI age adjusted comorbidity index 0 points;
  6. According to the adhesion risk scoring system of European Anti-Adhesions in Gynaecology Expert Panel (ANGEL), the adhesion risk was divided into three levels: high, medium and low. Subjects with low risk (0 to 12 points) and abdominal wall scarring and pelvic cavity B-ultrasonography do not indicate obvious pelvic cavity adhesion wiil be included.

Exclusion criteria

Exclusion Criteria:

  1. Moderate and high-risk patients will be excluded based on ANGEL adhesion risk scoring system;
  2. Subjects with hemorrhagic rupture of ectopic pregnancy and unstable vital signs;
  3. Genital tract infection or in the acute phase of systemic infection;
  4. Subjects on long-term anticoagulant therapy or with coagulation dysfunction;
  5. Subjects have severe heart and lung disease, liver and kidney dysfunction, and cannot tolerate anesthesia;
  6. A history of abdominal or diaphragmatic hernia, abnormal umbilical cord development, or umbilical surgery;
  7. Not willing to undergo endoscopic surgery;
  8. Participated in other drug and device clinical trials within 3 months before surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Other
    Domestic single-port laparoscopic surgery system group

    The domestic single-port robotic laparoscopic surgery system is a new minimally invasive surgical method. Compared with traditional laparoscopic surgery, it establishes the surgical approach through the natural scar umbilicus of the human body, thus bringing less trauma and beautiful experience to patients

    Device: Domestic single-port laparoscopic surgery system

Interventions

  • DeviceDomestic single-port laparoscopic surgery system

    The minimum distance of the single-port surgical system from the port is 5-7cm to obtain the instrument bending space. The load capacity of surgical tools is increased from 2N to 5N, which greatly improves the structural reliability. At the same time, it can realize 6 degrees of freedom movement。

06

What researchers measure

Primary outcomes

  1. Day Surgery Success Rate

    Day surgery success rate means that no other operation is performed during the operation and the patient is discharged within 48 hours.

    Time frame: Patient recruitment ends and all patients complete surgery, up to 2 years

Secondary outcomes

  1. Time of Operation

    Time of operation includes total operation time, operator teleoperation time, robot system parking time and instrument docking time。

    Time frame: From pre-surgery to the end of surgery,up to 12 hours

  2. Blood Loss Evaluation

    The estimated intraoperative blood loss and the difference of hemoglobin before and after operation.

    Time frame: From the time of hemoglobin measurement before surgery to the time of hemoglobin measurement after surgery, up to 1 day after surgery

  3. Surgeon Satisfaction Evaluation

    Surgeon satisfaction questionnaire

    Time frame: Up to 1 day after surgery

  4. Time of First Postoperative Anal Exhaust

    time recording

    Time frame: Up to 2 day after surgery

  5. First Spontaneous Urination Time

    Time recording

    Time frame: Up to 2 day after surgery

  6. Pain Score

    Visual Analogue Scale(VAS)

    Time frame: 4 hours after surgery

  7. Hospital Stays

    Time

    Time frame: From the date of admission to the Date of discharge, assessed up to 2 days

  8. Postoperative Rehabilitation Evaluation

    Quality of Life-15(QOL-15)

    Time frame: Within 1 day after surgery; 24 hours and 30 days after discharge

  9. Abdominal Incision Healing

    Observation

    Time frame: Within 1 day after surgery

  10. Scar Satisfaction

    Scar Cosmesis Assessment and Rating(SCAR)

    Time frame: 30 days after discharge

  11. Discharge Assessment

    Postanesthesia Discharge Score(PADS)

    Time frame: Within 1 day after surgery, 4 hours after discharge

  12. Postoperative Complication

    Telephone, Wechat official account and outpatient follow-up

    Time frame: 4 hours, 24 hours and 30 days after discharge

  13. Quality and Safety Evaluation of Day Surgery

    13 indexes of quality and safety evaluation of day surgery

    Time frame: 30 days after discharge

  14. Safety Evaluation

    6 indexes of safety evaluations

    Time frame: Day of surgery and within 1 day after surgery; 4 hours, 24 hours and 30 days after discharge

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2026, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 14, 2025
StartEst.
Apr 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06828419
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Apr 10, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 3, 2025

Study contacts

Xingyu Yang, Master
Contact
yangxy_822@163.com
+86 173 9805 4822
Ping Duan, Master
Contact
dppddpp@126.com
+86 135 8743 0406

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion